Evogene Receives Nasdaq Minimum Bid Price Deficiency Notice

On April 2, 2026, Evogene Ltd. (Nasdaq, TASE: EVGN) announced that it received a deficiency notification letter from the Nasdaq Stock Market LLC. The notice indicates that the company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of its ordinary shares has remained below $1.00 per share for 30 consecutive business days. Evogene has been granted an initial period of 180 calendar days, or until September 28, 2026, to regain compliance. To achieve this, the company's ordinary shares must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days. If compliance is not met by the deadline, Evogene may be eligible for an additional 180-day grace period, provided it meets other listing standards. The company stated it will consider all available options to rectify the deficiency, including a potential reverse stock split. The notification currently has no immediate impact on the listing or trading of Evogene's shares on the Nasdaq or the Tel Aviv Stock Exchange.